<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00879593</url>
  </required_header>
  <id_info>
    <org_study_id>ANTADIR PTcCO2/SLA</org_study_id>
    <nct_id>NCT00879593</nct_id>
  </id_info>
  <brief_title>Nocturnal PtcCO2 Monitoring in Patients With Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>Potential Role for Nocturnal PtcCO2 Monitoring in the Close Follow up of ALS Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motoneurons,
      with a prevalence around 5/100.000. Respiratory muscle involvement is a major feature in ALS
      and remains the main prognostic factor. Timing and rate of progression of this respiratory
      muscle involvement is also highly variable among individuals.

      Respiratory manifestations justify a careful follow up including clinical evaluation,
      pulmonary function tests and blood gases. Prognostic value of respiratory muscle assessment
      has been clearly demonstrated in ALS, although several cut off values have been published.
      The clinical benefit of non invasive ventilation (NIV) is well established in ALS, but the
      optimal criteria for its initiation remain debated .

      The 1999 consensus for NIV selected classical criteria to consider NIV in patients with
      respiratory symptoms suggesting hypoventilation: daytime hypercapnia (PaCO2 &gt; 45 mmHg),
      nocturnal SaO2 &lt; 89 % more than 5 consecutive minutes and for progressive neuromuscular
      disorders (NMD) (mainly ALS), a vital capacity (VC) &lt; 50 % pred or a PImax &lt; 60 cmH2O.

      Besides daytime clinical and PFT assessment, nocturnal evaluation is essential in ALS. The
      prevalence of sleep apnea ranges from 16 % to 76 %.

      Transcutaneous PCO2 (tcPCO2) is an attractive technique to evaluate non invasively nocturnal
      hypoventilation. The technique is well validated in different settings. Its use in
      neuromuscular disorders (NMD) is recent. In particular one study has demonstrated a high
      predictive value of tcPCO2 for the development of daytime hypoventilation within 1 year. To
      our knowledge, this technique has not been specifically assessed in ALS. There is a potential
      role for nocturnal PtcCO2 monitoring in the close follow up of ALS patients. Indeed, a close
      respiratory follow up of ALS patients is essential to determine the optimal timing of NIV,
      avoiding the occurence of unexpected acute respiratory failure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nocturnal Transcutaneous PCO2</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>PtcCO2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PtcCO2</intervention_name>
    <description>Nocturnal assessment will be performed during the initial polysomnography (and at 6 months) with a combined PtcCO2/pulse oxymetry TOSCA500 Radiometer monitoring evaluating different physiological parameters.</description>
    <arm_group_label>PtcCO2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Amyotrophic lateral sclerosis :definite, probable or probable with EMG (Airlie House
             Criteria, 1998).

          -  Forced vital capacity &gt;70% pred.

          -  Daytime PaCO2 &lt;43 mmHg.

          -  Venous HCO3- &lt;28 mmol/L

        Exclusion Criteria:

          -  Patients unable to perform pulmonary function tests or nocturnal recordings.

          -  Coexisting significant lung disease: moderate to severe asthma or COPD

          -  Current NIV, CPAP or oxygen therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry PEREZ, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU LILLE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PEREZ</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PÃ´le des maladies respiratoires et service EFR- Centre hospitalier Regional Universitaire</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2009</study_first_submitted>
  <study_first_submitted_qc>April 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2009</study_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche</investigator_affiliation>
    <investigator_full_name>DELRIEU Jacqueline</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

